Who manufactures Propa-Med and where is it produced?

Propa-Med is manufactured by Bioniche Pharma, a pharmaceutical company whose injectable production operates under GMP (Good Manufacturing Practice) conditions. The facility applies validated aseptic compounding, sterilising filtration, and closed-system filling processes. Each finished lot is released only after HPLC potency confirmation and LAL endotoxin testing are completed and archived against the lot number.

What does GMP certification mean for an injectable testosterone product?

GMP (Good Manufacturing Practice) is a regulatory framework requiring that injectables are produced in cleanroom-grade, environmentally controlled facilities with documented process validation at every stage. For Propa-Med, this means raw API is verified on receipt, compounding follows validated batch records, sterilising filtration is pressure-monitored, and no lot is released without instrument-confirmed potency and endotoxin data.

How does Bioniche Pharma's batch testing process work for Propa-Med?

Each Propa-Med batch undergoes a two-stage analytical release gate. HPLC chromatography measures the testosterone propionate concentration in the final filled product against a reference standard, confirming the 150mg/ml label claim within pharmacopoeial tolerances. A separate LAL endotoxin assay then quantifies bacterial endotoxin load in the injectable solution, with the result compared against parenteral acceptance limits before the lot is approved for release.

How does the 150mg/ml concentration affect dosing with an insulin syringe?

At 150mg/ml, each 0.1ml drawn corresponds to 15mg of testosterone propionate. A common 100mg dose therefore requires 0.67ml, drawable in a standard 1ml syringe. This higher concentration means smaller oil volumes per injection compared to 100mg/ml products — a practical advantage for frequent propionate administration — but demands accurate draw technique because each 0.1ml increment carries greater active mass.

What are the storage requirements for a Propa-Med 10ml vial after first use?

After initial puncture, the Propa-Med vial should be stored at 15–25°C, away from direct light and moisture. Refrigeration is not required but prolongs shelf integrity if ambient temperatures are variable. The vial must not be frozen. Each draw should use a fresh, sterile needle to maintain container-closure integrity across the multiple access events typical of a propionate protocol. (2) angle_used

Science Focus

Bioniche Pharma

Propa-Med 150mg/ml 10ml Vial by Bioniche Pharma

Name: Propa-Med
Brand: Bioniche Pharma
SKU: INJ-TPRO-BNI-150-030
Price: 35.00 EUR
Availability: InStock

Propa-Med is a 150mg/ml testosterone propionate injectable produced by Bioniche Pharma in a 10ml multi-dose vial, formulated under verified GMP conditions with documented batch traceability from API receipt through finished-product release. At 150mg/ml, it delivers 1500mg of active compound per vial — among the highest single-vial testosterone propionate loads in this concentration class. Potency and parenteral safety are confirmed at finished-product stage: HPLC concentration analysis and LAL endotoxin quantification are applied to every released batch, not delegated to supplier certificates alone.

€35.00Free shipping on orders over €300

In stock

Ships within 48 h Lab-tested batch

150mg/ml concentration delivers 50% more active compound per millilitre than standard 100mg/ml propionate vials, reducing total injection oil volume
HPLC-confirmed potency at finished-product stage — not inferred from API supplier documentation
LAL endotoxin release testing validates parenteral safety against pharmacopoeial limits for every batch
GMP-compliant aseptic compounding and sterilising filtration applied throughout production
10ml bromobutyl-stoppered vial with container-closure integrity verification supports multi-draw propionate protocols
Ester-specific in-process controls — filtration pressure, fill weight — calibrated to the physical properties of testosterone propionate at 150mg/ml
Lot-numbered batch documentation links each vial to its individual HPLC and LAL instrument records

Phase	Dosage	Note
Introductory / orientation	150–200mg/week (1.0–1.33ml total, split across 3 injections)	Allows GMP-verified potency to be assessed against individual androgen response before escalation
Maintenance / performance	300–400mg/week (2.0–2.67ml total, EOD or 3×/week)	Standard propionate maintenance range; each injection draws 0.67–0.89ml from the HPLC-released vial
Pre-competition / wind-down	150–200mg/week (1.0–1.33ml total)	Dose reduction exploits propionate's rapid ester clearance; smaller volumes per draw from the 150mg/ml vial

Key takeaways

Verify every Propa-Med batch via its archived HPLC chromatogram and LAL endotoxin report.
Confirm GMP-validated fill parameters are calibrated specifically for 150mg/ml propionate concentration.
Expect 1500mg of HPLC-verified testosterone propionate per single 10ml vial unit.
Use a fresh sterile needle for each draw to preserve multi-dose vial integrity.
Match dose volumes to the 15mg-per-0.1ml ratio for accurate per-injection load.

Bioniche Pharma's GMP Framework for Propa-Med 150mg/ml

Propa-Med is a finished-product injectable defined by its manufacturing architecture as much as its pharmacology: Bioniche Pharma produces this 150mg/ml testosterone propionate formulation under a GMP framework in which quality release depends on instrument-generated batch data rather than declaration alone. GMP (Good Manufacturing Practice) mandates that every stage of production — from aseptic compounding and sterilising filtration to closed-system filling and container-closure integrity — operates within validated, documented parameters. For an injectable androgen at 150mg/ml concentration, these controls are especially consequential because any formulation error or endotoxin exceedance is concentrated proportionally.

Batch Release Criteria: HPLC and LAL Testing

Bioniche Pharma subjects each Propa-Med lot to two independent analytical release criteria before dispatch. HPLC (high-performance liquid chromatography) quantifies the testosterone propionate content of the finished product against a certified reference standard, confirming that the declared 150mg/ml potency falls within pharmacopoeial acceptance tolerances — a standard tighter than label-claim rounding alone. Separately, LAL (Limulus Amebocyte Lysate) endotoxin testing measures bacterial endotoxin load in the filled injectable solution against parenteral acceptance limits established in major pharmacopoeias. Both the HPLC chromatogram and the LAL endotoxin value are archived against the individual lot number on each vial, creating an auditable release record.

Why the 150mg/ml Concentration Demands Tighter Process Control

Compared to standard 100mg/ml propionate preparations, a 150mg/ml fill increases the active API mass per unit volume by 50%, which narrows the acceptable variation window for both potency and excipient ratios. Bioniche Pharma's in-process controls — including filtration-pressure monitoring and fill-weight verification — are calibrated specifically to the physical properties of testosterone propionate at this higher concentration, not adapted from a generic injectable template. This ester-specific process design is documented in the product's manufacturing record and is referenced in the batch release certificate supplied with each lot.

Vial Format and Aseptic Access

The 10ml bromobutyl-stoppered vial supports multiple aseptic draws across a propionate cycle. Container-closure integrity is verified as part of the batch release sequence, ensuring that the elastomeric septum maintains a sterile barrier through repeated needle penetration events. The vial format also means that one HPLC-verified, LAL-tested unit serves an entire multi-week protocol, reducing the number of separately manufactured units a user must assess for quality consistency.

Usage

Inspect the vial: confirm the lot number on the label corresponds to a batch with documented HPLC and LAL release data — request the certificate of analysis if not supplied.
Verify the bromobutyl rubber septum is intact and the cap seal is unbroken before first draw.
Swab the septum with 70% isopropyl alcohol and allow to dry fully before each needle insertion to maintain aseptic access.
Draw the calculated volume using a fresh 1ml syringe — at 150mg/ml, every 0.1ml equals 15mg; calculate your target dose volume before drawing.
Administer via deep intramuscular injection (glute, vastus lateralis, or deltoid); rotate sites across the injection schedule to distribute oil depot load.
Store the vial at 15–25°C, protected from light; discard if particulate matter, cloudiness, or colour change is observed — these may indicate a breach of the GMP-validated sterile barrier.

Warnings

Contraindications: Propa-Med 150mg/ml is contraindicated where androgen-sensitive malignancy is present, including carcinoma of the prostate or breast. Additional contraindications encompass untreated polycythaemia, significant hepatic dysfunction, and documented hypersensitivity to testosterone propionate or any constituent of the oil-based vehicle. Administration to paediatric patients or women of reproductive age is not appropriate.

Side Effects: Injection-site discomfort, haematocrit elevation, seborrhoea, acne, and scalp hair thinning in genetically predisposed males are recognised adverse effects of testosterone propionate therapy. Peripheral aromatisation of testosterone to oestradiol may produce fluid accumulation and gynaecomastia in the absence of appropriate oestrogen management. The 150mg/ml concentration delivers a proportionally greater androgen dose per millilitre than standard-strength preparations; precise volumetric measurement is therefore essential to avoid unintended overdosing.

Monitoring: Prior to commencing therapy, baseline values for haematocrit, serum testosterone, LH, FSH, and oestradiol should be established. Repeat assessment at four-to-six-week intervals throughout the treatment period is advisable. Fasting lipid profiles and hepatic transaminase levels become relevant for protocols extending beyond short durations. Given the influence of exogenous androgens on erythropoiesis and vascular tone, blood pressure should be measured regularly throughout use.

PCT: The short half-life of the propionate ester results in comparatively rapid plasma clearance, permitting initiation of SERM-based post-cycle therapy — tamoxifen or clomiphene being the agents of choice — as early as three to five days following the concluding injection. Recovery of hypothalamic-pituitary-gonadal axis function proceeds at a rate that differs between individuals; a structured course of four to six weeks of SERM administration is generally warranted following performance-level androgen exposure.

Frequently asked questions

Who manufactures Propa-Med and where is it produced?: Propa-Med is manufactured by Bioniche Pharma, a pharmaceutical company whose injectable production operates under GMP (Good Manufacturing Practice) conditions. The facility applies validated aseptic compounding, sterilising filtration, and closed-system filling processes. Each finished lot is released only after HPLC potency confirmation and LAL endotoxin testing are completed and archived against the lot number.
What does GMP certification mean for an injectable testosterone product?: GMP (Good Manufacturing Practice) is a regulatory framework requiring that injectables are produced in cleanroom-grade, environmentally controlled facilities with documented process validation at every stage. For Propa-Med, this means raw API is verified on receipt, compounding follows validated batch records, sterilising filtration is pressure-monitored, and no lot is released without instrument-confirmed potency and endotoxin data.
How does Bioniche Pharma's batch testing process work for Propa-Med?: Each Propa-Med batch undergoes a two-stage analytical release gate. HPLC chromatography measures the testosterone propionate concentration in the final filled product against a reference standard, confirming the 150mg/ml label claim within pharmacopoeial tolerances. A separate LAL endotoxin assay then quantifies bacterial endotoxin load in the injectable solution, with the result compared against parenteral acceptance limits before the lot is approved for release.
How does the 150mg/ml concentration affect dosing with an insulin syringe?: At 150mg/ml, each 0.1ml drawn corresponds to 15mg of testosterone propionate. A common 100mg dose therefore requires 0.67ml, drawable in a standard 1ml syringe. This higher concentration means smaller oil volumes per injection compared to 100mg/ml products — a practical advantage for frequent propionate administration — but demands accurate draw technique because each 0.1ml increment carries greater active mass.
What are the storage requirements for a Propa-Med 10ml vial after first use?: After initial puncture, the Propa-Med vial should be stored at 15–25°C, away from direct light and moisture. Refrigeration is not required but prolongs shelf integrity if ambient temperatures are variable. The vial must not be frozen. Each draw should use a fresh, sterile needle to maintain container-closure integrity across the multiple access events typical of a propionate protocol. (2) angle_used

Manufacturer

Bioniche Pharma's specialisation within its injectable testosterone line extends to ester-level process differentiation: Propa-Med 150mg/ml is not manufactured using a generic injectable template scaled to a different concentration, but under a formulation-specific batch record in which compounding parameters — oil vehicle ratio, filtration pressure thresholds, fill-weight tolerances — are validated for the unique physicochemical properties of testosterone propionate at 150mg/ml. This ester-specific manufacturing discipline reflects the company's broader principle that each distinct propionate formulation requires its own analytical identity: a finished-product HPLC dataset and a LAL endotoxin result generated independently for that product's lot, archived under its unique lot number, and traceable from the point of QC release to the vial received by the end user. Bioniche Pharma's quality architecture treats the propionate ester as a compound with its own viscosity profile, esterase-cleavage kinetics, and concentration-dependent excipient interactions — factors that distinguish the production requirements for Propa-Med from those governing the company's enanthate or blend formulations, and that are reflected in separate, ester-specific validated manufacturing records.

Product details

Brand	Bioniche Pharma
Active ingredient	testosterone propionate
Also known as	Testosterone Propionate, Test P, Testovis, Propa-Med, Bioniche Pharma Testosterone Propionate
Strength	150 mg
Form	Vial
Pack size	1 piece
Item number	INJ-TPRO-BNI-150-030

Reviews

No reviews yet. Be the first to review this product.

Write a review

Reviews are written by users of this shop and are checked editorially before publication. Unless labelled “Verified purchase”, we do not verify that the review is based on an actual purchase.

Similar products

Propandrol 100mg/ml 10x1ml Ampoules by Balkan Pharmaceuticals

Established Brand

Propandrol 100mg/ml 10x1ml Ampullen by Balkan Pharmaceuticals

Propandrol is a pharmaceutical-grade injectable testosterone, historically the first esterified testosterone derivative to reach clinical practice, formulated by Balkan Pharmaceuticals as Testosterone Propionate at 100 mg per millilitre in individually sealed 1 ml glass ampoules. The propionate ester — first synthesised and trialled in the 1930s — remains the benchmark short-acting testosterone form against which all later esters have been compared by endocrinologists and sports scientists alike. Batch-level sterility and potency are confirmed through validated HPLC quantification and LAL endotoxin testing; every ampoule leaving the Chișinău facility carries a traceable lot code under EU GMP Annex 1 requirements.

€36.00

Optimal Dosage

Propha-Testosterone 100mg/ml 10ml Vial by Beligas Pharmaceuticals

Propha-Testosterone by Beligas Pharmaceuticals supplies Testosterone Propionate at 100 mg/ml in a sterile 10 ml multi-dose vial — an intramuscular injectable whose short-ester architecture routes the compound directly into systemic circulation, bypassing the hepatic first-pass degradation that renders oral testosterone formats pharmacokinetically inferior. Each vial supports precise volumetric dose control across recomposition and performance phases, with plasma testosterone maintained consistently within an active physiological window throughout the cycle. Batch release is contingent on passing a dual analytical gate: reversed-phase HPLC potency confirmation and LAL endotoxin clearance, both documented per lot under GMP-compliant manufacturing conditions.

€35.00

Testopin-100 100mg/ml 10x1ml Ampoules by BM Pharmaceuticals

Fast Acting

Testopin-100 100mg/ml 10x1ml Ampullen by BM Pharmaceuticals

Testopin-100 is a short-ester testosterone injectable — Testosterone Propionate at 100 mg/ml — engineered for rapid onset of action, delivering measurable anabolic activity within 24–48 hours of the first injection due to Propionate's characteristically brief half-life of approximately 2–3 days. Each ampoule in this 10×1ml format provides a precisely dosed, single-use sterile unit that supports frequent administration schedules designed to maintain stable blood concentrations. Quality is assured through validated HPLC potency testing and LAL endotoxin screening at batch release; every ampoule meets pharmaceutical-grade sterility criteria before leaving the BM Pharmaceuticals facility.

€38.00

High Concentration

PropiTrex 150mg/ml 10ml Vial by Concentrex Labs

PropiTrex by Concentrex Labs delivers Testosterone Propionate at 150 mg/ml in a sterile 10 ml multi-dose vial, purpose-engineered for athletes who schedule injections around specific training days and precise clock windows. Each millilitre carries 50% more active androgen than standard 100 mg/ml propionate preparations, compressing effective dose volumes and making frequent, day-specific administration more practical. Sterility and potency are confirmed through LAL endotoxin testing and HPLC quantification at batch release; every vial exits the Concentrex Labs facility only after passing documented aseptic-processing controls.

€35.00

Stack it with

Pairs well with these products.

High Concentration

Quant-Equipoise 300mg/ml 10ml Vial by Beligas Pharmaceuticals

Quant-Equipoise by Beligas Pharmaceuticals is a high-concentration injectable anabolic agent delivering 300 mg of Boldenone Undecylenate per millilitre in a 10 ml multi-dose vial, purpose-built for integration into contemporary cycle structures where weekly injection frequency and volume efficiency are primary design criteria. The compound's extended ester profile supports low-frequency administration windows that align with modern 7-day dosing blocks used in both bulking and body-recomposition protocols. Quality assurance is enforced at two independent checkpoints: HPLC-verified potency assay and LAL bacterial endotoxin testing — both completed before batch release under Beligas's GMP-certified production framework.

€47.00

Bolden-250 250mg/ml 10x1ml Ampoules by BM Pharmaceuticals

Long-Acting Formula

Bolden-250 250mg/ml 10x1ml Ampullen by BM Pharmaceuticals

Bolden-250 is a veterinary-derived anabolic compound reformulated for human performance use, delivering Boldenone Undecylenate at 250 mg/ml via single-dose ampoule — distinguished by its exceptionally prolonged plasma half-life of approximately 14 days, which governs the entire pharmacokinetic profile and dictates injection scheduling. The undecylenate ester attached to the boldenone base controls the rate of hydrolysis in muscle tissue, producing a slow, steady release curve that maintains stable serum concentrations over extended periods. Quality verification is built into every step of production: HPLC-confirmed potency, LAL endotoxin screening, and GMP-compliant fill-finish at BM Pharmaceuticals' certified facility.

€48.00

Brand Quality

EquiTrex 350mg/ml 10ml Vial by Concentrex Labs

EquiTrex is a high-concentration boldenone undecylenate injectable — 350 mg per millilitre in a 10 ml vial — engineered to serve distinct roles across both the blast and cruise phases of a structured performance cycle. Its extended ester release supports stable androgen exposure during lower-dose cruise periods while delivering meaningful anabolic output when dose is escalated during a blast. Quality assurance at Concentrex Labs is built on HPLC potency verification and LAL endotoxin screening; every released batch carries documented evidence of sterility and concentration accuracy.

€52.00

Pro Choice

EQ 300 300mg/ml 10ml Vial by Dragon-Pharma

Dragon-Pharma EQ 300 delivers Boldenone Undecylenate at 300 mg/ml in a 10 ml multi-dose vial, formulated specifically for older athletes and TRT-adjacent users who require a mild yet effective anabolic agent to complement age-related hormonal management strategies. Its gradual plasma release profile makes it particularly suited to the steadier hormonal environment that men over 40 typically need to maintain lean mass, bone density support, and nitrogen retention without the volatility of shorter-ester androgens. Quality is assured at the batch level: every vial passes HPLC content verification and LAL endotoxin screening before release under full GMP compliance.

€44.00